Last Updated on
July 26, 2022
AbbVie Ventures—also known as AbbVie Biotech Venture—is a venture capital firm focused on investing in groundbreaking scientific research. By collaborating with leading scientists, it seeks to gain access to the next generation of scientific advancements.
The firm was founded in 2009 in North Chicago, Illinois as a subsidiary of AbbVie Inc. Until 2012 AbbVie Inc. was a business running under Abbott Laboratories. However, in 2013 it launched itself as a new biopharmaceutical company and was listed on the New York Stock Exchange as ABBV.
Since its establishment, the company has invested around $50 billion in early-stage pharma and life sciences startups for the discovery, development, and commercialization of new therapies and medicines — especially in areas with unmet medical needs.
With its 48,000 employees worldwide, the firm is striving to innovate and invest in entrepreneurs with novel solutions for the world’s critical health challenges. Its current development efforts are focused on the following key therapeutic areas:
AbbVie Ventures has its offices across three major locations in the United States:
In this article, we will review the innovation and investment interests of AbbVie Ventures, its partnerships, and the companies that gained the venture investments.
AbbVie Ventures funds the development and delivery of innovative medicines and therapeutics that have the potential to improve patients’ lives. The 75% of medicines in its pipelines are the first of their kind. Moreover, it supports R&D for the most pressing healthcare issues in 20 countries worldwide.
Its innovation and investments have saved the lives of around 57 million people in more than 60 countries with a plethora of critical disease conditions. Below is a brief summary on AbbVie’s focus areas and its contribution in those fields.
The AbbVie oncology team combines biology knowledge with cutting-edge technologies, such as cellular therapies, antibody drug conjugates (ADCs), and targeted protein degradation, to treat and manage multiple cancer types.
Its focused areas in cancer treatment include:
AbbVie Ventures is committed to bringing innovative, disease-modifying solutions to treat the most challenging neurologic diseases. It strives to improve patients’ lives by removing barriers to their care and developing research that provides access to better treatments.
For now, its labs are focused on developing therapeutics in the following neurologic disease areas:
AbbVie considers itself responsible for removing the hurdles to hepatitis C care and freeing the world from the Hepatitis C virus (HCV). Since 2017, the company has been a part of projects related to the global elimination of HPV.
Below is the timeline and the efforts made by AbbVie in HPV elimination:
Abbvie acquired Allergan — a company developing eye care solutions for 70 years — and combined their expertise to restore patients’ vision by building innovative products and therapies.
The company holds its reputation worldwide for its innovation in the following eye care areas:
AbbVie is on the lookout for partners who can help them deliver innovative medicines and improve patients’ lives. Currently, the company has research partnerships with more than 220 biotech companies, universities, nonprofits, and government agencies.
The firm is mainly interested in partnering with companies that share similar interests in R&D areas like neuroscience, hepatology, neurodegenerative diseases, oncology, cystic fibrosis, and women’s health.
Each year, AbbVie Ventures targets six to eight new investments, primarily at the seed and series A stage. Its current investment portfolio comprises around 20 companies that are based in Europe and the U.S., and work in oncology, immunology, and neuroscience.
A few examples of AbbVie’s portfolio companies are:
AbbVie Ventures is a corporate venture capital arm of AbbVie Inc. dedicated to funding emerging biotech, life science, and pharmaceutical companies that work on the world’s most pressing healthcare issues. Among its primary areas of focus are oncology, immunology, virology, and neurodegenerative diseases.
The company has invested about $50 billion in transformative research and is committed to improving patients’ lives through partnerships with companies and organizations with similar visions.
Obtaining venture capital is often a battle for biotech companies because of the risks involved and the time it takes to develop a new product.
However, it becomes easier if you have a motivated team and convincing experimental credentials to get the investors’ attention. Here, cutting-edge equipment and lab tools play a major role to produce clean, reliable and validated data.
But, what if you’re short on funds to acquire high-tech lab equipment?
Excedr’s leasing program can be your best alternative in such a case. It helps companies lease all their desired equipment rather than purchase and spend huge amounts of their budget on upfront costs.
Our leasing program offers flexible terms that can be customized to fit your financial and operational needs, significantly reduces upfront costs, and includes comprehensive repair and maintenance coverage.
We have a wide range of equipment available, including biotech equipment, analytical instruments, and clinical tools, which can enhance your research experience and bring you the peace of mind you need to turn your lab ideas into reality.
Don’t have the budget to purchase lab equipment outright? Consider leasing through Excedr to save your lab time and money. Browse your leasing options today!